QuietMIND Foundation is a public non-profit research foundation and an outpatient healthcare practice. We provide neurofeedback therapy within the Great Philadelphia region. Our staff includes internationally recognized, highly-trained, professionals drawn from the fields of biofeedback and neuropsychology, neurophysiology, functional medicine, neuropsychiatry, neuroscience research, organizational consulting, and the law.
We also rely on the skills of staff and professionally trained volunteers to design and deliver our marketing and advertising campaigns, and perform some of our administrative functions. We have a national and worldwide network of professionals we consult with to assist us. We actively train and involve our interns in the fundamental work necessary for developing and conducting applied clinical research projects including writing grant proposals, educational programs and maintaining our library and institutional contacts.
We also rely on the skills of staff and professionally trained volunteers to design and deliver our marketing and advertising campaigns, and perform some of our administrative functions. We have a national and worldwide network of professionals we consult with to assist us. We actively train and involve our interns in the fundamental work necessary for developing and conducting applied clinical research projects including writing grant proposals, educational programs and maintaining our library and institutional contacts.
|
|
Marvin H. Berman, Ph.D., C.B.T.,
Founder & President
Dr. Berman earned his Master’s and PhD in Psychoeducational Processes from Temple University, where he studied group and organizational behavior. He obtained certification in Bioenergetic Analysis at the Philadelphia Institute for Bioenergetic Analysis in 1983. He has participated in post-graduate training workshops and seminars in Systems-Centered Therapy, and the Feldenkrais Method. He was certified in EEG biofeedback in 2003. Dr. Berman currently consults to senior executives and management teams on the application of cognitive neuroscience in leadership development and performance. Berman is a leader in expanding the application of EEG biofeedback and related technologies in treating neurodegenerative and neuropsychiatric disorders.
Jeffrey Leighton, PhD
Director of Neuromodulation Research
Dr. Jeffrey Leighton is a goal-driven, innovative, and highly committed professional with a strong background in psychology and extensive experience in both academic and corporate settings. Dr. Leighton possesses a unique blend of expertise in psychology and business. He has delivered impactful grand rounds lectures at hospitals and provided engaging presentations about new qEEG/LORETA imaging techniques at universities, fostering a warm and supportive learning environment while maximizing interest in the latest advancements in diagnostic imaging.
Moreover, Dr. Leighton has excelled in leadership roles and project management within academic and corporate environments, demonstrating a high level of commitment to advocacy, diversity, research, and a unified educational mission. As a professor, he has developed various university psychology courses for traditional and remote learning platforms, designed and executed quasi-experimental research studies using neuromodulating techniques, and managed substance abuse research and behavioral assessment programs. Dr. Leighton's communication and interpersonal abilities have allowed him to establish positive working relationships with students, faculty, staff, business professionals, and community partners. This diverse background reflects his ability to apply his expertise and leadership skills in psychology and business, making him a versatile professional capable of driving new neuromodulatory research and success at QMF.
Moreover, Dr. Leighton has excelled in leadership roles and project management within academic and corporate environments, demonstrating a high level of commitment to advocacy, diversity, research, and a unified educational mission. As a professor, he has developed various university psychology courses for traditional and remote learning platforms, designed and executed quasi-experimental research studies using neuromodulating techniques, and managed substance abuse research and behavioral assessment programs. Dr. Leighton's communication and interpersonal abilities have allowed him to establish positive working relationships with students, faculty, staff, business professionals, and community partners. This diverse background reflects his ability to apply his expertise and leadership skills in psychology and business, making him a versatile professional capable of driving new neuromodulatory research and success at QMF.
Trent W Nichols MD
Medical Director, Quietmind Foundation
Trent W Nichols MD is a Northwestern University Med School grad and Postdoc Internal Med and Gastroenterology. His research has been in pharmaceutical clinical trials, nutraceuticals with "Optimal Digestive Health" a book for the public and 2 textbooks.
He pioneered the development of moderate magnetic field therapy involving zero point and 0.5T magnetic therapy for neurodegenerative disorders. He joined QMF to advance the development of self-administered applications of his pioneering work in noninvasive therapeutics. Dr. Nichols is also the Chief Medical Officer for the International Cancer Association for Education and Research (ICARE).
He pioneered the development of moderate magnetic field therapy involving zero point and 0.5T magnetic therapy for neurodegenerative disorders. He joined QMF to advance the development of self-administered applications of his pioneering work in noninvasive therapeutics. Dr. Nichols is also the Chief Medical Officer for the International Cancer Association for Education and Research (ICARE).
Adam Stamm
Assistant Executive Director
Adam Stamm is an alumni of Albright College. He has worked with Quietmind Foundation since 2019. Adam begin his involvement at Quietmind Foundation as a volunteer. He met Marvin Berman and learned about the Quietmind Foundation while traveling from Philadelphia, PA to Denver on a plane. He was fascinated by the concepts and research and couldn't wait to get involved.
Adam is responsible for helping manage various administrative tasks such as website updates, social media accounts, and QMF Newsletters. As a marketing and communications professional, Adam has helped to promote and organize research studies around photobiomodulation for QMF.
Paul Chazot, PhD, Scientific Advisory Board Member, Dept. of Biosciences, Durham University, Durham UK.
Dr. Chazot has produced a significant body of research on the mechanisms and clinical application of 1068-1080nm pulsed photobiomodulation. He has been the basic science mentor for QMF and leading advocate for the exploration of PBM as a potential disease-modifying intervention strategy, who with Dr. Gordon Dougal MD, BSEE have been the driving force behind the development of the Cognitolite technology. Quietmind Fdn. was fortunate to be chosen to conduct the first human clinical trials using the 1070nm PBMT device in 2009 and over the next 15 years, now with our study partners at Baylor Research Institute in Temple, TX
Allan Lundy, Ph.D., IRB Chairman
Dr Lundy earned his PhD in Social Psychology from Harvard University in 1981. Between 1992 and 2003 he was on the faculty of the Department of Psychiatry at Jefferson Medical College. During that time, he published 32 articles and book chapters. In his last six years at Jefferson he was Principal Investigator on NIH and other grants totaling over two million dollars. Since 2003 he has been an independent consultant in research methods and statistical analysis.
Dr. Chazot has produced a significant body of research on the mechanisms and clinical application of 1068-1080nm pulsed photobiomodulation. He has been the basic science mentor for QMF and leading advocate for the exploration of PBM as a potential disease-modifying intervention strategy, who with Dr. Gordon Dougal MD, BSEE have been the driving force behind the development of the Cognitolite technology. Quietmind Fdn. was fortunate to be chosen to conduct the first human clinical trials using the 1070nm PBMT device in 2009 and over the next 15 years, now with our study partners at Baylor Research Institute in Temple, TX
Allan Lundy, Ph.D., IRB Chairman
Dr Lundy earned his PhD in Social Psychology from Harvard University in 1981. Between 1992 and 2003 he was on the faculty of the Department of Psychiatry at Jefferson Medical College. During that time, he published 32 articles and book chapters. In his last six years at Jefferson he was Principal Investigator on NIH and other grants totaling over two million dollars. Since 2003 he has been an independent consultant in research methods and statistical analysis.
Quietmind Foundation
Please send all mail to:
C/O Adam Stamm Asst Executive Director
1819 S Hicks St
Philadelphia PA 19145
New Jersey Office
145 La Quinta Dr.
Egg Harbor, NJ 08234
Minnesota Office:
C/O Adam Stamm Asst Executive Director
1819 S Hicks St
Philadelphia PA 19145
New Jersey Office
145 La Quinta Dr.
Egg Harbor, NJ 08234
Minnesota Office:
